MyeLink Platform

The AI Operating System
for Pharmaceutical R&D

From scientific question to IND-ready output.
Autonomously.

Request Access See how it works ↓
Scroll

The Bottleneck

Drug development is slow because knowledge synthesis doesn't scale.

R&D teams spend the majority of their time aggregating literature, reconciling findings, and drafting documents — not making decisions.

$0
Median cost to bring a novel drug to market approval Wouters et al., JAMA 2020
0
To complete IND-enabling safety studies for a novel small molecule FDA / industry consensus
0
Of drugs entering Phase 1 clinical trials fail before reaching approval FDA data / DiMasi et al.

Multi-Agent Orchestration

Not a chatbot.
Not a copilot.
An autonomous R&D team.

MyeLink deploys a network of specialized AI scientists — each with deep domain expertise — that research, debate, synthesize, and produce outputs continuously. When a finding surfaces in pharmacology, the regulatory strategist re-evaluates the IND pathway in real time.

  • → Continuous autonomous research cycles, 24/7
  • → Cross-domain debate before any output is issued
  • → Escalation to human decision-makers when needed
  • → Every output traceable to its evidence chain

Real Outputs

From the engine. Not a demo.

Every output type below has been produced autonomously inside OrthoTreat's own IND pipeline.

Regulatory Brief
PMOA Classification: Drug-Device Combination Under 21 CFR Part 3
IND-ready jurisdictional argument produced autonomously from literature and regulatory precedent. Submitted to FDA review process.
IND-enabling · 12 pages
Genotoxicity Waiver
Lovastatin Class Waiver Justification
ICH-aligned waiver argument grounded in published safety data. Reduces costly genotoxicity study requirements.
Safety package · 8 pages
Scientific Analysis
Endogenous vs Exogenous BMP-2: Safety-Efficacy Paradigm
Mechanism deep-dive positioning ModulX against Infuse (rhBMP-2). Investor and advisor-ready with full evidence chain.
Track A · 6 min read
IND Simulation
Phase 1 IND Test Bench — 6-Drug Series
Full IND readiness simulations across 6 drug candidates. Surfaces gaps before CRO spend is committed.
Validated · 479 tests
CRO Protocol
OT-RAT-001 In Vivo Study Protocol
Partner-ready study protocol drafted to GLP standards. Directly used in the CRO tender process within 48 hours of output.
GLP-aligned · CRO-ready
Competitive Context
§21 Competitive Landscape & Fast Track Precedent
Market positioning, competitor pipeline mapping, and Fast Track designation precedent identification for bone regeneration.
BD-ready · Regulatory context

The Platform

Your pipeline. Your agents. Your outputs.

MyeLink is available as a licensed SaaS platform. Configure the agent network for your therapeutic area, your regulatory pathway, your stage of development.

⬡

Deploy

Onboard in days, not months. MyeLink connects to your existing knowledge base — literature, internal documents, regulatory filings — and is operational immediately.

  • No infrastructure to manage
  • Secure isolated tenant environment
  • Existing document ingestion
⬡

Configure

Tune the agent network to your domain. Set the regulatory pathway (IND, CE Mark, PMDA), therapeutic area, and pipeline stage. Agents adapt their expertise accordingly.

  • Therapeutic area specialization
  • Regulatory pathway mapping
  • Custom output templates
⬡

Scale

Run multiple programs in parallel. MyeLink operates 24/7 — while your team focuses on decisions, the engine handles synthesis, monitoring, and drafting.

  • Parallel pipeline coverage
  • Continuous literature monitoring
  • Audit-ready output provenance

Early Access

Ready to deploy
your R&D engine?

MyeLink is in selective early access. We work closely with founding partners to configure the platform for their specific pipeline.

sahar@orthotreat.io

OrthoTreat Ltd. · Israel